Earnings Releases·Nov 9, 2026, 4:08 PM ET

Zymeworks — Third Quarter 2026 Earnings Summary

Revenue surged to $256.5 million in Q3 2026 from $27.6 million in the prior year period, driven by a $250.0 million FDA approval milestone from Jazz Pharmaceuticals for Ziihera, resulting in a net income of $173.7 million versus a $19.6 million net loss previously.
The company raised full-year 2026 guidance to $337–$351 million in revenue and $176–$190 million in Adjusted EBITDA, contingent on the expiration of the HSR waiting period for the Roche collaboration.
Strategic capital allocation included the acquisition of Theravance Biopharma on September 23, 2026, and $14.0 million in share repurchases during the quarter, bringing total YTD buybacks to $140.4 million.
Future outlook remains strong with Ziihera receiving NCCN and ESMO recommendations, a new $55 million upfront payment from Roche for ZW209, and expectations to eliminate $13–$15 million in annualized overhead post-acquisition.